Melanotan 1

Product Overview: Melanotan 1 (MT-1 / Afamelanotide)

Melanotan 1 (MT-1, also known as Afamelanotide) is a linear synthetic peptide analog of naturally occurring Alpha-Melanocyte-Stimulating Hormone ($\alpha$-MSH). Engineered with specific amino acid substitutions ([Nle⁴, D-Phe⁷]-$\alpha$-MSH), MT-1 possesses significantly greater resistance to enzymatic degradation and extended biological potency compared to native $\alpha$-MSH. Unlike cyclic Melanotan 2, Melanotan 1 exhibits high selectivity for the Melanocortin-1 Receptor (MC1R) expressed on dermal melanocytes, making it a primary research candidate for investigating photoprotection, targeted eumelanin synthesis, and photodermatoses.

Primary Research Applications & Reasons for Study

• Selective Dermal MC1R Activation: Binding with high affinity to melanocyte MC1R to activate adenylate cyclase and upregulate intracellular cAMP, driving tyrosinase gene expression.
• Eumelanin Synthesis & Photoprotection: Stimulating the production of dark, photo-protective eumelanin rather than reddish pheomelanin to reduce UV-induced thymine dimer formation and skin damage.
• Photodermatosis Research Models: Investigating protective signaling in erythropoietic protoporphyria (EPP), polymorphic light eruption (PLE), and solar urticaria tissue assays.
• Anti-Inflammatory Dermal Signaling: Assessing secondary anti-inflammatory cascades and reduction of pro-inflammatory cytokines in UV-exposed epidermal cell models.

Expected Research Results & Timeline Metrics

• Phase 1 / Hours 1–24
  MC1R Binding & cAMP Elevation: High-affinity binding to dermal melanocytes triggers an immediate surge in intracellular cAMP, setting the enzymatic cascade for melanin production.
• Phase 2 / Days 3–7
  Tyrosinase Activation & Pigmentation Onset: Statistically significant increases in tyrosinase activity, leading to measurable increases in skin tissue eumelanin density and initial photoprotective coverage.
• Phase 3 / Weeks 2–4
  Peak Eumelanin Density & UV Resistance: Sustained dark pigmentation across epidermal tissue samples, accompanied by significant reductions in UV-induced apoptosis and DNA mutation markers.

Key Research Benefits

• Selective Dermal Action: Higher relative specificity for MC1R compared to MT-2, greatly minimizing central nervous system side effects (such as spontaneous arousal or nausea).
• Sunless Melanogenesis Model: Induces robust eumelanin synthesis without requiring prior exposure to damaging UV radiation.
• Enhanced Enzymatic Stability: D-Phe⁷ and Nle⁴ amino acid modifications provide extended plasma survival over native linear $\alpha$-MSH.
• Clinical Translation Control: Serves as the key reference peptide for FDA-approved clinical applications in photo-intolerant conditions (Afamelanotide).